Gill-Samuel v. Nova Biomedical Corp.

298 F.R.D. 693, 2014 WL 1661496, 2014 U.S. Dist. LEXIS 59374
CourtDistrict Court, S.D. Florida
DecidedApril 8, 2014
DocketNo. 13-62591-CIV
StatusPublished
Cited by13 cases

This text of 298 F.R.D. 693 (Gill-Samuel v. Nova Biomedical Corp.) is published on Counsel Stack Legal Research, covering District Court, S.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gill-Samuel v. Nova Biomedical Corp., 298 F.R.D. 693, 2014 WL 1661496, 2014 U.S. Dist. LEXIS 59374 (S.D. Fla. 2014).

Opinion

ORDER GRANTING IN PART AND DENYING IN PART MOTION TO DISMISS, AND DENYING MOTION TO STRIKE CLASS ACTION ALLEGATIONS

ROBIN S. ROSENBAUM, District Judge.

This cause is before the Court upon Defendant Nova Biomedical Corporation’s Motion to Dismiss [ECF No. 8] and Motion to Strike Class Action Allegations [ECF No. 9]. The Court has reviewed the Motions, all supporting and opposing filings, and the record in this case. For the reasons set forth below, the Court grants in part and denies in part Nova’s Motion to Dismiss and denies Nova’s Motion to Strike Class Action Allegations.

BACKGROUND

On November 27, 2013, Plaintiff Robin Gill-Samuel’s state-court Class Action Complaint was removed to this Court. See ECF No. 1. Plaintiffs Complaint brings claims of product liability and negligence against Defendant Nova Biomedical Corporation (“Nova”), a manufacturer of prescription blood-glucose test strips. ECF No. 1-1 at 5-8, ¶¶ 25-38. Nova announced a voluntary recall of 62 million of its test strips on July 29, 2013. Id. at ¶ 2. The recalled test strips are alleged to have reported abnormally high blood-glucose readings. Id. at 3, ¶ 12.

In December 2012, Plaintiff used Nova’s test strips and, because of a blood-glucose reading that Plaintiff alleges was falsely high due to the product defect, Plaintiff sought medical treatment that was later determined to be unnecessary. Id. ¶ 13. In August 2013, Plaintiff received a letter from her pharmacy indicating that Plaintiff had received one or more test strips whose lot number was included in the recall. Id. ¶ 14. Plaintiff brings this action on behalf of all persons who purchased Nova’s test strips that were subject to the July-August 2013 recall and, in addition, on behalf of a subclass of these persons who incurred additional medically related expenses as a result of the strips’ improper test results. Id. at 3-4, ¶¶ 15,16.

DISCUSSION

I. Motion to Dismiss

A. Rule 12(b)(6) Standard

Rule 12(b)(6), Fed.R.Civ.P., governs motions to dismiss. That rule provides, in relevant part,

[696]*696(b) How to Present Defenses. Every defense to a claim for relief in any pleading must be asserted in the responsive pleading if one is required. But a party may assert the following defenses by motion:
(6) failure to state a claim upon which relief can be granted;____

Id. The Court, therefore, considers the Federal Rules of Civil Procedure as they set forth the requirements for stating a claim.

Rule 8(a)(2), Fed.R.Civ.P., demands that a pleading contain “a short and plain statement of the claim showing that the pleader is entitled to relief.” Fed.R.Civ.P. 8(a)(2). While a complaint need not provide detailed factual allegations, the standard “requires more than labels and conclusions, and a formulaic recitation of the elements of a cause of action will not do.” Ashcroft v. Iqbal, 556 U.S. 662, 679, 129 S.Ct. 1937, 173 L.Ed.2d 868 (2009) (citing Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555, 127 S.Ct. 1955, 167 L.Ed.2d 929 (2007)); see also Wilchombe v. TeeVee Toons, Inc., 555 F.3d 949, 958 (11th Cir.2009); Corbitt v. Home Depot U.S.A., Inc., 573 F.3d 1223, 1256 (11th Cir.2009); Cobb v. State of Florida, 293 Fed.Appx. 708, 709 (11th Cir.2008); Watts v. Fla. Int’l Univ., 495 F.3d 1289, 1295 (11th Cir.2007). “[N]aked assertion[s]” bereft of “further factual enhancement” do not suffice. Twombly, 550 U.S. at 555, 557, 127 S.Ct. 1955. As the Supreme Court has explained, a complaint’s “factual allegations must be enough to raise a right to relief above the speculative level.” Id. at 555, 127 S.Ct. 1955. “Moreover, the facts supporting the claim must be ‘consistent with the allegations in the complaint.’ ” Wilchombe, 555 F.3d at 958 (quoting Twombly, 550 U.S. at 562, 127 S.Ct. 1955). On a motion to dismiss, the Court should accept the non-conclusory allegations in the complaint as true and evaluate all plausible inferences derived from those facts in favor of the plaintiff. See Hughes v. Lott, 350 F.3d 1157, 1159-60 (11th Cir.2003) (internal citation omitted); see also Cobb, 293 Fed.Appx. at 709; Brown v. Budget Rent-A-Car Syst., Inc., 119 F.3d 922, 923 (11th Cir.1997).

Courts therefore conduct a “two-pronged approach” when considering a motion to dismiss under Rule 12(b)(6). Iqbal, 556 U.S. at 679, 129 S.Ct. 1937. A court should first ask whether the pleading properly asserts “well-pleaded factual allegations” or whether, instead, it merely asserts “‘legal conclusions’ [that are] not entitled to the assumption of truth.” Id. at 679-680, 129 S.Ct. 1937 (quoting Twombly, 550 U.S. at 555, 127 S.Ct. 1955). If the complaint contains factual allegations that are well pled, the court should assume their veracity and then move to the next step, asking whether the factual allegations “plausibly give rise to an entitlement to relief.” Id. at 679, 129 S.Ct. 1937. Thus, where the pleading asserts non-conclusory, factual allegations that, if true, would push the claim “across the line from conceivable to plausible,” the motion to dismiss should be denied. Id. at 680, 129 S.Ct. 1937 (quoting Twombly, 550 U.S. at 570, 127 S.Ct. 1955) (quotation marks omitted).

B. Economic-Loss Rule

Plaintiff brings two claims in tort against Nova — for product liability and negligence — but Nova’s Motion to Dismiss asserts that these claims are barred by the economic-loss rule. ECF No. 8 at 8-9. Florida law provides for an economic-loss rule that prohibits a party in a product-liability case from suing in tort for “disappointed economic expectations” because these types of claims are generally protected by contract law, rather than tort law. Tiara Condo. Ass’n, Inc. v. Marsh & McLennan Companies, Inc., 110 So.3d 399, 400 (Fla.2013), opinion appended in full at Tiara Condo. Ass’n, Inc. v. Marsh & McLennan Companies, Inc., 714 F.3d 1253 (11th Cir.2013) (quoting Sensenbrenner v. Rust, Orling & Neale, Architects, Inc., 236 Va. 419, 374 S.E.2d 55, 58 (1988)). Though over the years courts have expanded the applicability of the economic-loss rule, in Tiara Condominium Association, Inc. v. Marsh & McLennan Companies, Inc., 110 So.3d 399 (Fla.2013), the Florida Supreme Court, upon a question certified by the Eleventh Circuit Court of Appeals, receded from prior case law to hold that the economic-loss rule applies to product-liability cases only. Id. at 400.

As the Tiara

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
298 F.R.D. 693, 2014 WL 1661496, 2014 U.S. Dist. LEXIS 59374, Counsel Stack Legal Research, https://law.counselstack.com/opinion/gill-samuel-v-nova-biomedical-corp-flsd-2014.